IOVA in focus: Iovance Biotherapeutics posts $99M second-quarter revenue, beats its own guidance by more than 10%
In focus for IOVA: an August 2026 corporate overview filed with the SEC shows Iovance Biotherapeutics generated approximately $99 million in second-quarter revenue, a print the company described as more than 10% above…
Key takeaways
- Iovance Biotherapeutics reported approximately $99 million in second-quarter 2026 revenue, more than 10% above its own 2Q26 guidance and about 66% year-over-year growth.
- The company held roughly $304 million in cash and investments as of June 30, 2026, with runway projected into the second half of 2028.
- Gross margin from cost of sales exceeded 95% (excluding depreciation and amortization), signaling the TIL manufacturing model is holding at commercial scale.
- Amtagvi is the first and only approved treatment in second-line-plus advanced melanoma, an indication Iovance values at $1 billion or more in U.S. sales potential.
- More than 95 treatment centers were active or nearly ready across the U.S., Canada, and Australia as of August 5, 2026, putting about 66% of addressable patients within 200 miles of an authorized center.
In focus for IOVA: an August 2026 corporate overview filed with the SEC shows Iovance Biotherapeutics generated approximately $99 million in second-quarter revenue, a print the company described as more than 10% above its own 2Q26 guidance. The figure reflects roughly 66% year-over-year quarterly revenue growth. Cash, cash equivalents, short-term investments, and restricted cash totaled approximately $304 million as of June 30, 2026, with runway projected into the second half of 2028.
The numbers behind the beat
Gross margin from cost of sales came in above 95%, excluding depreciation and amortization. That single metric matters most for a TIL therapy company: Amtagvi requires individualized manufacturing at the Iovance Cell Therapy Center, and a margin above that level tells the market the model is holding at commercial scale. More than 95 treatment centers were active or in final stages of readiness as of August 5, 2026, spanning the United States, Canada, and Australia. Approximately 66% of addressable patients live within 200 miles of an authorized treatment center, which is the number that maps most directly to prescribing reach rather than regulatory approval alone.
Amtagvi's commercial position in melanoma and beyond
Amtagvi holds the regulatory position of first and only approved treatment in second-line-plus advanced melanoma. Iovance has treated approximately 2,000 patients across its commercial and clinical TIL programs in total. The company sets U.S. sales potential at $1 billion or more in that 2L-plus melanoma indication. The same slides identify a roughly 7x expansion of the U.S. opportunity if Amtagvi reaches second-line metastatic non-small cell lung cancer, specifically the nonsquamous subset without EGFR, ROS1, or ALK genomic mutations.
What to watch
The next confirmable clinical milestone for IOVA is the planned registrational trial in advanced sarcomas. Iovance disclosed in the filing that the trial carries an explicit risk of not supporting approval. Sitting upstream of any NSCLC regulatory discussion is an interim data cut from October 10, 2025, covering patients with nonsquamous metastatic non-small cell lung cancer using a minimum cell dose aligned to FDA feedback from the melanoma program. That read is the data event the setup requires before an NSCLC filing timeline becomes a conversation worth having.